ArticleClinical and experimental immunology2023

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Merryn Voysey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.